1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Zelnorm's Return: US FDA Panel Hands Down Split Decision On Constipation Drug's Target Population

 
• By Michael Cipriano

Seven advisory committee members said the treatment for irritable bowel syndrome with constipation should be labeled for females at low cardiovascular risk; three panelists, including two cardiologists, supported a narrower indication limited to low CV risk patients who also suffer from severe symptoms.

FDA Advisory Committee Feature image

The US FDA may have its hands full deciding how to limit the use of US WorldMeds LLC's 5-HT4 receptor agonist Zelnorm (tegaserod maleate), a drug designed for the treatment for irritable bowel syndrome with constipation (IBS-C), after an advisory committee delivered a split vote over the most appropriate target population.

On Oct. 17, seven of 12 members of the Gastrointestinal Drugs Advisory Committee voted that they expect the benefits of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 
• By Bridget Silverman

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.